Marksans Pharma's UK Subsidiary Relonchem Secures Multiple MHRA Approvals
Marksans Pharma's wholly owned UK subsidiary, Relonchem Ltd., has received marketing authorisation from the Medicines and Healthcare products Regulatory Agency (MHRA) for Metformin Hydrochloride Relonchem Prolonged Release Tablets in three strengths—500 mg, 750 mg, and 1000 mg.
Relonchem Ltd | 18/08/2025 | By Dineshwori | 256
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy